Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Could NICE Pilot Projects Be An Opportunity For Multinationals In China’s County Hospital Market?

This article was originally published in PharmAsia News

Executive Summary

In a bid to control overspending and improve healthcare service quality in rural areas, the Chinese government is piloting health technology assessment projects in county-level hospitals, armed with technical support from the UK’s NICE.

You may also be interested in...



China's Residents Health Card Offers Potential For Massive Data Mining

China plans to issue electronic medical cards to 50% of its residents by the end of the year in a new commitment to overhaul the country's healthcare system and strengthen capacity to handle the sheer volume of Chinese patients

Behind The First Inhaled COVID Vaccine: Chinese-Language CEO Podcast With CanSino’s Xuefeng Yu

After securing the first approval globally for an inhaled COVID-19 vaccine, Chinese biotech CanSino CEO Xuefeng Yu sat down with Scrip in this Chinese-language interview to share his views on vaccine development and market opportunities in China and elsewhere.

China Drug Price Negotiations: Another Race To The Bottom?

With the fourth quarter just around the corner, China's closely-watched annual drug reimbursement and prices negotiations are entering a key final stage. But will applicants need to be more strategic than expedient?

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC082496

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel